Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Impact of Emblica Officinalis (Amla) on Lipid Profile, Glucose, and C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Publisher Pubmed



Setayesh L1 ; Haghighat N2 ; Rasaei N3 ; Rezaei M3 ; Casazza K4 ; Nadery M5 ; Yamrali I3 ; Zamani M6 ; Asbaghi O7, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE, United States
  2. 2. Laparoscopy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  3. 3. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. The Water School, Florida Gulf Coast University, FL, United States
  5. 5. Ph.D. Student at the Department of Dietetics and Nutrition Robert Stempel College of Public Health & Social Work Florida International University, United States
  6. 6. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  8. 8. Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews Published:2023


Abstract

Background and aims: Emblica Officinalis (Amla) is a plant often utilized in traditional medicine due to its purported anti-inflammatory, antioxidant, hypoglycemic, and hypolipidemic properties. However, current evidence regarding its potential for preventing and treating metabolic abnormalities associated with chronic diseases remains unclear. Methods: This systematic review and meta-analysis aimed to examine the effects of Amla supplementation on lipid profile, glucose, and C-reactive protein (CRP) concentrations in adults. We completed a systematic search (current as of December 2022) of all available randomized controlled trials (RCTs) in the database including ISI Web of Science, PubMed, Scopus, and Embase. Any effect's mean difference (MD) was calculated using a random-effects model. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated also calculated using a random-effects model. Results: Five RTCs were included in the meta-analysis. Following Amla supplementation, pooled results showed a significant reduction in CRP (p = 0.002), fasting blood glucose (FBG) (p < 0.001), low-density lipoprotein cholesterol (LDL-c) (p < 0.001), total cholesterol (TC) (p < 0.001), and serum triglyceride (TG) (p < 0.001) concentrations as well as an increase in high-density lipoprotein cholesterol (HDL-c) (p < 0.001). The baseline concentration of biochemical indicators was used for subgroup analysis. Conclusion: Amla supplementation shows promise for improving metabolic parameters in adults. In general, the populations included in the analysis were generally 40–58 years with an average BMI of 25.5 and a length of intervention ranging from 3 to 12 weeks. Thus additional investigations are warranted to confirm and expand the findings presented herein. © 2023
Experts (# of related papers)
Other Related Docs